Automate Your Wheel Strategy on MEDP
With Tiblio's Option Bot, you can configure your own wheel strategy including MEDP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MEDP
- Rev/Share 75.682
- Book/Share 5.8446
- PB 78.5719
- Debt/Equity 0.725
- CurrentRatio 0.4267
- ROIC 1.148
- MktCap 12900867460.0
- FreeCF/Share 20.2083
- PFCF 21.6485
- PE 32.3738
- Debt/Assets 0.0795
- DivYield 0
- ROE 0.6766
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MEDP | UBS | Neutral | Sell | -- | $305 | July 29, 2025 |
| Downgrade | MEDP | TD Cowen | Hold | Sell | -- | $366 | July 23, 2025 |
| Initiation | MEDP | Barclays | -- | Equal Weight | -- | $300 | June 24, 2025 |
| Downgrade | MEDP | William Blair | Outperform | Market Perform | -- | -- | April 22, 2025 |
| Downgrade | MEDP | TD Cowen | Buy | Hold | -- | $328 | April 14, 2025 |
| Initiation | MEDP | Leerink Partners | -- | Market Perform | -- | $330 | March 24, 2025 |
| Downgrade | MEDP | Robert W. Baird | Outperform | Neutral | $413 | $349 | Oct. 23, 2024 |
| Initiation | MEDP | Redburn Atlantic | -- | Buy | -- | -- | Oct. 14, 2024 |
| Downgrade | MEDP | UBS | Buy | Neutral | $420 | $350 | Sept. 27, 2024 |
| Downgrade | MEDP | Jefferies | Buy | Hold | $415 | $345 | Sept. 25, 2024 |
News
Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Medpace (MEDP) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $2.97 per share. This compares to earnings of $2.46 per share a year ago.
Read More
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Results Revenue for the three months ended December 31, 2024 increased 7.7% to $536.6 million, compared to $498.4 million for the comparable prior-year period. On a constant currency basis, revenue for the fourth quarter of 2024 increased 7.8% compared to the fourth quarter of 2023. Backlog as.
Read More
Medpace Holdings, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
About Medpace Holdings, Inc. (MEDP)
- IPO Date 2016-08-11
- Website https://www.medpace.com
- Industry Medical - Diagnostics & Research
- CEO August James Troendle
- Employees 5900